These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 21584931

  • 21. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B.
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [Abstract] [Full Text] [Related]

  • 22. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
    Hou HA, Yao M, Tang JL, Chen YK, Ko BS, Huang SY, Tien HF, Chang HH, Lu MY, Lin TT, Lin KH, Hsiao CH, Lin CW, Chen YC.
    Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
    [Abstract] [Full Text] [Related]

  • 23. Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
    Ruf S, Moser O, Wössmann W, Kreyenberg H, Wagner HJ.
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):50-4. PubMed ID: 21178708
    [Abstract] [Full Text] [Related]

  • 24. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF, Fan ZP, Luo XD, Sun J, Zhang Y, Ding YQ.
    Transpl Infect Dis; 2010 Aug 01; 12(4):284-91. PubMed ID: 20345506
    [Abstract] [Full Text] [Related]

  • 25. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, Wynn RF.
    Pediatr Blood Cancer; 2006 Aug 01; 47(2):200-5. PubMed ID: 16206207
    [Abstract] [Full Text] [Related]

  • 26. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab.
    van der Velden WJ, Mori T, Stevens WB, de Haan AF, Stelma FF, Blijlevens NM, Donnelly JP.
    Bone Marrow Transplant; 2013 Nov 01; 48(11):1465-71. PubMed ID: 23749107
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement.
    Hänel M, Fiedler F, Thorns C.
    Onkologie; 2001 Oct 01; 24(5):491-4. PubMed ID: 11694778
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
    Johnston A, Salles G, Espinouse D, Felman P, André P, Berger F, Coiffier B.
    Clin Lymphoma Myeloma; 2008 Dec 01; 8(6):356-8. PubMed ID: 19064401
    [Abstract] [Full Text] [Related]

  • 31. Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome.
    Ho AY, Adams S, Shaikh H, Pagliuca A, Devereux S, Mufti GJ.
    Bone Marrow Transplant; 2002 May 01; 29(10):867-9. PubMed ID: 12058237
    [Abstract] [Full Text] [Related]

  • 32. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 01; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 33. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
    Ali S, AlThubaiti S, Renzi S, Krueger J, Chiang KY, Naqvi A, Schechter T, Punnett A, Ali M.
    Pediatr Transplant; 2019 Feb 01; 23(1):e13319. PubMed ID: 30417487
    [Abstract] [Full Text] [Related]

  • 34. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
    Zilz ND, Olson LJ, McGregor CG.
    J Heart Lung Transplant; 2001 Jul 01; 20(7):770-2. PubMed ID: 11448808
    [Abstract] [Full Text] [Related]

  • 35. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug 01; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 36. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
    Ohga S, Kudo K, Ishii E, Honjo S, Morimoto A, Osugi Y, Sawada A, Inoue M, Tabuchi K, Suzuki N, Ishida Y, Imashuku S, Kato S, Hara T.
    Pediatr Blood Cancer; 2010 Feb 01; 54(2):299-306. PubMed ID: 19827139
    [Abstract] [Full Text] [Related]

  • 37. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY, Zhao SS, Wang XK, Wang L, Wang FY, Fang S, Liu ZX, Guan LX, Liu YC, Ding Y, Dou LP, Wang LL, Gao CJ.
    Ann Transplant; 2019 Apr 03; 24():175-184. PubMed ID: 30940797
    [Abstract] [Full Text] [Related]

  • 38. [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation].
    Liu QF, Fan ZP, Luo XD, Zhang Y, Sun J.
    Zhonghua Yi Xue Za Zhi; 2008 Dec 02; 88(44):3123-6. PubMed ID: 19159594
    [Abstract] [Full Text] [Related]

  • 39. [Treatment of post-transplant lymphoproliferative disease with rituximab].
    Jiang YJ, Wang X.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun 02; 22(3):852-6. PubMed ID: 24989308
    [Abstract] [Full Text] [Related]

  • 40. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder presenting with skin involvement after CD34-selected autologous peripheral blood stem cell transplantation.
    Takahashi S, Watanabe D, Miura K, Ozawa H, Tamada Y, Hara K, Matsumoto Y.
    Eur J Dermatol; 2007 Jun 02; 17(3):242-4. PubMed ID: 17478388
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.